S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:EXEL

Exelixis - EXEL Stock Forecast, Price & News

$17.56
-0.06 (-0.34%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$17.09
$17.68
50-Day Range
$15.41
$17.71
52-Week Range
$14.87
$23.40
Volume
3.30 million shs
Average Volume
3.03 million shs
Market Capitalization
$5.66 billion
P/E Ratio
18.48
Dividend Yield
N/A
Price Target
$27.58

Exelixis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
57.1% Upside
$27.58 Price Target
Short Interest
Healthy
3.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.63
Upright™ Environmental Score
News Sentiment
0.34mentions of Exelixis in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$984,800 Sold Last Quarter
Proj. Earnings Growth
73.58%
From $0.53 to $0.92 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.19 out of 5 stars

Medical Sector

8th out of 1,053 stocks

Biological Products, Except Diagnostic Industry

3rd out of 170 stocks


EXEL stock logo

About Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

Four Undervalued Healthcare Stocks for 2023 (EXEL)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $27.45
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Exelixis: Building On A Blockbuster
Is Exelixis Stock a Buy Now?
This Drug Developer Is My Stock Cure for 2023
See More Headlines
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Company Calendar

Last Earnings
11/02/2021
Today
2/02/2023
Next Earnings (Confirmed)
2/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
954
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$27.58
High Stock Price Forecast
$42.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+57.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$231.06 million
Pretax Margin
23.43%

Debt

Sales & Book Value

Annual Sales
$1.64 billion
Cash Flow
$0.78 per share
Book Value
$6.99 per share

Miscellaneous

Free Float
313,207,000
Market Cap
$5.66 billion
Optionable
Optionable
Beta
0.69

Social Links


Key Executives

  • Michael M. MorrisseyMichael M. Morrissey
    President, Chief Executive Officer & Director
  • Christopher J. SennerChristopher J. Senner
    Chief Financial Officer & Executive Vice President
  • Dana T. Aftab
    Chief Scientific Officer & Executive VP-Discovery
  • Vicki L. Goodman
    Chief Medical Officer & Executive Vice President
  • Jeffrey J. HessekielJeffrey J. Hessekiel
    Secretary, Executive VP & General Counsel













EXEL Stock - Frequently Asked Questions

Should I buy or sell Exelixis stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings
or view top-rated stocks.

What is Exelixis' stock price forecast for 2023?

9 Wall Street analysts have issued 1-year target prices for Exelixis' shares. Their EXEL share price forecasts range from $20.00 to $42.00. On average, they expect the company's share price to reach $27.58 in the next twelve months. This suggests a possible upside of 57.1% from the stock's current price.
View analysts price targets for EXEL
or view top-rated stocks among Wall Street analysts.

How have EXEL shares performed in 2023?

Exelixis' stock was trading at $16.04 at the beginning of 2023. Since then, EXEL shares have increased by 9.5% and is now trading at $17.56.
View the best growth stocks for 2023 here
.

When is Exelixis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our EXEL earnings forecast
.

How can I listen to Exelixis' earnings call?

Exelixis will be holding an earnings conference call on Tuesday, February 7th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "7374267".

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.19 by $0.07. The biotechnology company had revenue of $328.42 million for the quarter, compared to analysts' expectations of $366.34 million. Exelixis had a trailing twelve-month return on equity of 13.11% and a net margin of 18.78%. During the same period last year, the business earned ($0.10) EPS.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $415.00 million-$415.00 million, compared to the consensus revenue estimate of $414.83 million.

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Meditor Group Ltd (2.05%), Stephens Investment Management Group LLC (1.25%), Assenagon Asset Management S.A. (0.63%), Allspring Global Investments Holdings LLC (0.55%), Scout Investments Inc. (0.33%) and New York State Common Retirement Fund (0.31%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends
.

How do I buy shares of Exelixis?

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $17.56.

How much money does Exelixis make?

Exelixis (NASDAQ:EXEL) has a market capitalization of $5.66 billion and generates $1.64 billion in revenue each year. The biotechnology company earns $231.06 million in net income (profit) each year or $0.95 on an earnings per share basis.

How many employees does Exelixis have?

The company employs 954 workers across the globe.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.

This page (NASDAQ:EXEL) was last updated on 2/2/2023 by MarketBeat.com Staff